Patents Assigned to INSTITUT JEAN PAOLI & IRENE CALMETTES
-
Patent number: 11914083Abstract: This dosimeter comprises: a transducer material capable, when it is excited by a secondary ionizing radiation, of generating photons or electric charges, an amplifying layer capable, in response to its excitation by the primary ionizing radiation, of generating the secondary ionizing radiation. This amplifying layer comprises a first and a second amplifying sublayer stacked on top of one another. The first and the second amplifying sublayers are composed of at least 70%, by weight, respectively, of at least one first and one second material, the atomic numbers of which are greater than or equal to 29. The atomic number of the first material being less than the atomic number of the second material. The first sublayer is interposed between the second sublayer and the transducer material.Type: GrantFiled: September 1, 2020Date of Patent: February 27, 2024Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCERInventors: Sree Bash Chandra Debnath, Julien Darreon, Carole Fauquet, Didier Tonneau, Agnès Tallet
-
Patent number: 11904004Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: GrantFiled: June 9, 2020Date of Patent: February 20, 2024Assignees: INSERM, UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CNRS, UNIVERSITE DE NANTESInventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
-
Publication number: 20240034791Abstract: The present invention relates to antibodies having specificity to Nectin-4 and uses thereof.Type: ApplicationFiled: March 31, 2022Publication date: February 1, 2024Applicants: EMERGENCE THERAPEUTICS AG, UNIVERSITE D’AIX-MARSEILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE – CNRS –Inventors: Jack ELANDS, Florence LHOSPPICE, Xavier PRÉVILLE, Daniel OLIVE, Marc LOPEZ
-
Publication number: 20240002521Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERAAN BIOTECHNOLOGY, UNIVERSITE D'AIX MARSEILLE, UNIVERSITÉ PARIS CITÉ, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Publication number: 20240002522Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.Type: ApplicationFiled: November 19, 2021Publication date: January 4, 2024Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT JEAN PAOLI & IRENE CALMETTES, ALDERANN BIOTECHNOLOGY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE PARIS CITE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jerome GIUSTINIANI, Anne MARIE-CARDINE, Amaud FOUSSAT, Jemila HOUACINE
-
Patent number: 11572409Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.Type: GrantFiled: September 21, 2018Date of Patent: February 7, 2023Assignees: IMCHECK THERAPEUTICS SAS, INSERM, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, CNRSInventors: Daniel Olive, Christine Pasero
-
Publication number: 20220251232Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.Type: ApplicationFiled: May 20, 2020Publication date: August 11, 2022Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE PARIS, ALDERAAN BIOTECHNOLOGY, UNIVERSITE PARIS EST CRETEIL VAL DE MARNEInventors: Daniel OLIVE, Armand BENSUSSAN, Jérôme GIUSTINIANI, Arnaud FOUSSAT
-
Patent number: 11225481Abstract: This invention relates to xanthine derivative compounds that are inhibitors of BET bromodomains proteins, the method of preparation thereof and applications thereof.Type: GrantFiled: December 27, 2016Date of Patent: January 18, 2022Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Xavier Morelli, Sébastien Combes, Jean-Claude Guillemot, Stéphanie Betzi, Yves Collette, Philippe Roche, Adrien Lugari, Sabine Milhas, Brigitt Raux, Iuliia Voitovich
-
Patent number: 11180556Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: April 23, 2018Date of Patent: November 23, 2021Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Publication number: 20200376104Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: ApplicationFiled: June 9, 2020Publication date: December 3, 2020Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE NANTESInventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
-
Patent number: 10745482Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: August 6, 2019Date of Patent: August 18, 2020Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Jean Paoli & Irene Calmettes, Universite d' Aix-Marseille, Universite Claude Bernard—Lyon 1, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Patent number: 10716838Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: GrantFiled: February 22, 2019Date of Patent: July 21, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX MARSEILLE, UNIVERSITE DE NANTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRSInventors: Daniel Olive, Marc Bonneville, Emmanuel Scotet, Christelle Harly, Yves Guillaume
-
Patent number: 10675357Abstract: The present invention relates to antibodies having specificity to nectin-4 and uses thereof.Type: GrantFiled: September 7, 2016Date of Patent: June 9, 2020Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Marc Lopez, Daniel Olive
-
Patent number: 10633446Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.Type: GrantFiled: June 26, 2019Date of Patent: April 28, 2020Assignees: INSERM (Institut National de la Santéet de la Recherche Medicale), Institut Jean Paoli & Irene Calmettes, Universitéd'Aix-Marseille, Universite Claude Bernerd—Lyon }, Centre Leon BerardInventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
-
Publication number: 20190201513Abstract: Described herein are anti-CD277 antibodies which: activates or inhibit the cytolytic function of V?9/V?2 T cells, and/or costimulates T cells together with CD3-TCR, and/or costimulates T cells in addition to CD28-B7 costimulation, and/or increases the activity and/or survival of monocytes and dendritic cells. The use of said antibodies in therapy is also described.Type: ApplicationFiled: February 22, 2019Publication date: July 4, 2019Applicants: Institut National de la Santé et de la Recherche Médicale (INSERM), Universite D'Aix-Marseille, Institut Jean Paoli & Irene Calmettes, Centre National De La recherche Scientifique (CNRS), Universite De NantesInventors: Daniel OLIVE, Marc BONNEVILLE, Emmanuel SCOTET, Christelle HARLY, Yves GUILLAUME
-
Patent number: 10316315Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.Type: GrantFiled: February 8, 2017Date of Patent: June 11, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE D'AIX-MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Daniel Baty, Patrick Chames
-
Patent number: 10287360Abstract: The present invention relates to anti-Epidermal Growth Factor Receptor (EGFR) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.Type: GrantFiled: May 22, 2015Date of Patent: May 14, 2019Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale, Université d' Aix-Marseille, Centre National de la Recherche Scientifique (CNRS), CISBIO Bioassays, Institut Jean Paoli & Irene CalmettesInventors: Daniel Baty, Patrick Chames, Damien Nevoltris, Gérard Mathis
-
Patent number: 10174115Abstract: The present invention relates to anti-metabotropic glutamate receptor subtype 2 (mGluR2) conformational single domain antibodies and uses thereof in particular in the therapeutic and diagnostic field.Type: GrantFiled: July 3, 2015Date of Patent: January 8, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, UNIVERSITÉ D'AIX MARSEILLE, UNIVERSITE DE MONTPELLIER, CISBIO BIOASSAYS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ PARIS-SUDInventors: Daniel Baty, Jean-Philippe Pin, Patrick Chames, Damien Nevoltris, Philippe Rondard, Pauline Scholler, Gérard Mathis
-
Patent number: 10174117Abstract: The present invention relates to anti-HER2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer.Type: GrantFiled: June 11, 2014Date of Patent: January 8, 2019Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTESInventors: Daniel Baty, Patrick Chames, Brigitte Kerfelec, Marc Turini
-
Publication number: 20180327499Abstract: The present invention relates to anti-Natural Killer Group 2 member D (NKG2D) single domain antibodies and uses thereof in particular in the therapeutic field.Type: ApplicationFiled: November 10, 2016Publication date: November 15, 2018Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ D'AIX MARSEILLE, INSTITUT JEAN PAOLI & IRENE CALMETTES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (CNRS)Inventors: Daniel BATY, Patrick CHAMES, Brigitte KERFELEC, Elise TERMINE